Lymphoglobuline (equine anti-thymocyte globulin) / Sanofi 
Welcome,         Profile    Billing    Logout  
 7 Diseases   14 Trials   14 Trials   107 News 


12»
  • ||||||||||  Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
    Allograft-Educated Platelets for Gene Profiling of Acute Rejection After Heart Transplantation (Room 312) -  Jan 19, 2025 - Abstract #ISHLT2025ISHLT_2196;    
    P
    The recipients received induction with thymoglobuline, followed by tacrolimus, mycophenolic mofetil, and prednisolone maintenance immunosuppression...Initial findings also show that platelet gene expression profiling can accurately detect occurrence and severity of acute cellular rejection following heart transplantation (Figure 1).Conclusion This study proposes a novel approach to diagnosing acute rejection in heart transplant recipients. By directly comparing dd-cfDNA levels and the platelet transcriptome with EMB transcriptomics, the research aims to confirm the efficacy of non-invasive methods, improve diagnostic accuracy, reduce patient burden from surveillance EMB, and enhance long-term outcomes in heart transplantation.
  • ||||||||||  Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi, Rituxan (rituximab) / Roche
    Up-Front Matched Unrelated Donor Transplantation in Pediatric Patients with Idiopathic Aplastic Anemia: A Phase II Feasibility Study, on Behalf of Soci (Halls G-H (San Diego Convention Center)) -  Nov 6, 2024 - Abstract #ASH2024ASH_3334;    
    GvHD prophylaxis was ciclosporine A from D-1 to D365 associated to methotrexate 8mg/m2 D+1,+3 and+6...Finally, up-front HSCT from MUD for pts below the age of 18y presenting with SAA appears safe when the donor is available within 75-90 days. Rituximab is mandatory to lower the risk of EBV-PTLD for both prophylaxis and early pre-emptive treatment.If the donor recruitment is delayed, immune-suppressive therapy has to be preferred and promptly started.
  • ||||||||||  Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
    Decreased Chronic GvHD with Post-Transplant Cyclophosphamide (PTCY) Compared to ATG in Patients with Myelofibrosis Allografted with Unrelated Donor: A Study from the Chronic Malignancies Working Party of the EBMT (Halls G-H (San Diego Convention Center)) -  Nov 6, 2024 - Abstract #ASH2024ASH_3242;    
    Background Prospective randomized trials have reported a benefit for anti-thymoglobuline (ATG)-based graft-versus-host disease (GvHD) prophylaxis in the setting of allogeneic hematopoietic stem cell transplantation (alloHSCT) using unrelated donors (UD)...Cox (cause-specific) proportional hazards models were used to obtain adjusted estimates of the effect of PTCY compared to ATG on all endpoints, with a predefined set of adjustment factors (age, DIPSS, donor HLA matching, prior ruxolitinib, comorbidity score, MF subtype (PMF vs sMF)) and a frailty term for transplant center...PTCY is a valid option and considering availability and costs of ATG this may offer a good choice/alternative for regions which do have difficulties to have access to ATG. However, engraftment remains an issue in this setting.
  • ||||||||||  Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi, Lymphoglobuline (equine anti-thymocyte globulin) / Sanofi, Grafalon (rabbit anti-T-lymphocyte globulin) / Mundipharma, NeoPharm
    Journal:  A Comparative Analysis of Low Dose Grafalon (Pubmed Central) -  Nov 4, 2024   
    Due to the shift of donor preference to alternate donors, reliance on rabbit-ATG (rATG) has increased. In our study, Grafalon
  • ||||||||||  Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi, Lymphoglobuline (equine anti-thymocyte globulin) / Sanofi
    Enrollment closed, Trial completion date, Trial primary completion date:  Evaluation of 3 Different Doses of IV Busulfan (clinicaltrials.gov) -  Oct 8, 2024   
    P2,  N=177, Active, not recruiting, 
    In our study, Grafalon Unknown status --> Active, not recruiting | Trial completion date: Dec 2018 --> Jul 2026 | Trial primary completion date: Dec 2018 --> Jul 2026
  • ||||||||||  Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
    LONG-TERM OUTCOME OF ALLOGENEIC TRANSPLANTATION IN PRIMARY AND SECONDARY MYELOFIBROSIS (ePoster area) -  Feb 14, 2024 - Abstract #EBMT2024EBMT_1943;    
    All conditioning regimens were reduced intensity with fludarabine and busulfan 8-10mg/kg (roral or equivalent intravenous dose) and all patients received Thymoglobuline as GVHD prophylaxis... Allogeneic transplantation is a valid option for patients with higher risk of myelofibrosis with very good long-term results.
  • ||||||||||  Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
    DE NOVO APICAL HYPERTROPHY POST CARDIAC TRANSPLANT (Hall B4-5) -  Jan 26, 2024 - Abstract #ACC2024ACC_4943;    
    New apical hypertrophy is a rare finding post-heart transplant. Its clinical sequel remains unknown.
  • ||||||||||  Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
    Preclinical, Review, Journal:  Comparison of Different Rabbit Anti-Thymocyte Globulin Formulations in the Prophylaxis of Graft-Versus-Host Disease: A Systematic Review. (Pubmed Central) -  Sep 9, 2023   
    We subjected to scrutiny a total of five studies, of which four compared the differences between Thymoglobulin (ATG-T) and Grafalon (ATG-G), and one discussed the impact of ATG-T dose...However, data on aGvHD grades III-IV, GRFS, moderate-severe cGvHD, and CMV reactivation is conflicting. Through our research, we sought to summarise the most recent findings concerning r-ATGs in allo-HCT, and provide insight into the differences between the targets and origin of various ATG formulations.
  • ||||||||||  Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi, Lymphoglobuline (equine anti-thymocyte globulin) / Sanofi, NN1213 / Novo Nordisk
    Trial completion, Enrollment change:  The Efficacy of Immunosuppressive Therapy Combined With Cord Blood Transfusion in Treatment of Severe Aplastic Anemia (clinicaltrials.gov) -  Mar 17, 2023   
    P4,  N=60, Completed, 
    Ceramide concentrations were affected by AHSCT and associated with leukocyte counts and were altered three months after treatment, suggesting a long-lasting effect. Recruiting --> Completed | N=120 --> 60
  • ||||||||||  Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
    HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) TO TREAT ACTIVATED PI3K? SYNDROME (APDS) (ePoster Area) -  Feb 11, 2023 - Abstract #EBMT2023EBMT_1817;    
    Recruiting --> Completed | N=120 --> 60 Patients with APDS had suffered recurrent respiratory tract infections, bronchiectasis, autoimmunity, and non-neoplastic lymphoproliferation, eg. The current treatment options for APDS including immunoglobulin replacement, mTOR inhibition with sirolimus and selective PI3 K?inhibitors, eg. Hematopoietic stem cell transplantation (HSCT) has also been used in patients...2 m g /Kg Q 6 h
  • ||||||||||  Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
    HAPLOIDENTICAL STEM CELL TRANSPLANTATION WITH EX-VIVO T-DEPLETION IN PRIMARY IMMUNODEFICIENCY AND IMMUNE REGULATORY SYNDROMES: A MULTICENTER EXPERIENCE (ePoster Area) -  Feb 11, 2023 - Abstract #EBMT2023EBMT_1807;    
    Patients with APDS had suffered recurrent respiratory tract infections, bronchiectasis, autoimmunity, and non-neoplastic lymphoproliferation, eg. The current treatment options for APDS including immunoglobulin replacement, mTOR inhibition with sirolimus and selective PI3 K?inhibitors, eg. Hematopoietic stem cell transplantation (HSCT) has also been used in patients...2 m g /Kg Q 6 h Characteristics of the 48 haplo-HSCTsCharacteristicsn%DiagnosisPIDD #PIRD ##3216 66.733.3HaploplatformTCR ab+/CD19+ negative selectionCD3+/CD19+ negative selectionCD34+ positive selection34131 70.827.12.1Karnofsky/Lansky at Haplo 60741 14.685.4Conditioning regimensFlu-based*Bus-basedTreo-based**No conditioning194205 39.68.341.710.4RadiotherapyYesTLI / 4 GyTBI 4 GyNo86240 16.7 83.3SerotherapyATG
  • ||||||||||  Jakafi (ruxolitinib) / Novartis, Incyte, Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
    Improved Overall Survival in Patients with Acute GvHD with Ruxolitinib - a Single Center Experience () -  Dec 16, 2022 - Abstract #TCTASTCTCIBMTR2023TCT_ASTCT_CIBMTR_1002;    
    Before Ruxolitinib became available for aGVHD therapy, patients with steroid-refractory aGVHD (SR-aGVHD) were treated with thymoglobuline, high dose dexamethasone, etanercept, and/or extracorporeal photopheresis (ECP)...Overall survival at 2 years after aGVHD was 53% (95% CI 45%-64%) and 64% (95% CI 57%-75%), respectively (P=0.04). A clinically meaningful improvement in the overall survival of patients with acute GVHD was observed after the introduction of ruxolitinib into clinical praxis.
  • ||||||||||  Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
    Trial completion, Trial completion date:  Efficacy and Safety Study of ATG for Prophylaxis of aGVHD in Matched Sibling Donor PBSCT (clinicaltrials.gov) -  May 24, 2022   
    P4,  N=100, Completed, 
    Best outcomes are seen in patients with favourable HCT-CI and low/intermediate risk DRI. Recruiting --> Completed | Trial completion date: Dec 2025 --> Apr 2022
  • ||||||||||  Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
    Low-Dose Aspirin is More Critical Than Statins in Preventing Transplant Renal Artery Stenosis (Hynes Halls C & D: Board No. A196) -  May 20, 2022 - Abstract #ATC2022ATC_3260;    
    All patients were treated with thymoglobuline before surgery, and the post-operative immunosuppressive maintenance regimen was CNI+ mycophenolate mofetil/mycophenolate sodium + prednisone... Low-dose aspirin plays a key role in the prevention of TRAS and is significantly effective in patients without arterial plaque formation.
  • ||||||||||  Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
    HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) TO TREAT PURE RED CELL APLASIA (PRCA) (ePoster Area [VIRTUAL]) -  Jan 30, 2022 - Abstract #EBMT2022EBMT_1312;    
    Nevertheless, because of the risk of transplant-related death, careful selection of HSCT candidates and the optimal timing of HSCT is necessary. Future studies need to examine the PRCA patient characteristics that are likely to result in a successful HSCT as well as the optimal time for a patient to undergo transplantation.
  • ||||||||||  Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
    Clinical, Review, Journal:  Early stage of antibody-mediated rejection after lung transplantation： A case report and literature review. (Pubmed Central) -  Dec 17, 2021   
    The patient was functionally recovered after combined treatment with thymoglobuline, rituximab, plasmapheresis, and immunoglobulin...Transbronchial transplantation lung biopsy and the presence of serum donor-specific antibody are helpful to the diagnosis. The treatment should be preemptive and a comprehensive approach should be adopted.
  • ||||||||||  Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
    INVASIVE PULMONARY ASPERGILLOSIS AFTER HEART TRANSPLANTATION () -  Sep 23, 2021 - Abstract #ESOT2021ESOT_1378;    
    The development of IPA was associated with a combination of risk factors: optimal selection of doses of immunosuppressive therapy, prevention of neutropenia. In challenging cases surgical interventions helps to differentiate the disease.
  • ||||||||||  Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi, Zarzio (filgrastim biosimilar) / Novartis
    [VIRTUAL] THE IMPACT OF PRETRANSPLANT BODY MASS INDEX ON OUTCOMES OF ALLOGENEIC STEM CELL TRANSPLANTATION () -  May 13, 2021 - Abstract #EHA2021EHA_732;    
    Graft-versus host disease (GVHD) prophylaxis consisted of cyclosporine and short course of methotrexate...However, obese patients have a significantly lower OS compared with other patients (78% vs 92%, p=0.004 ) without impact on RFS (72% vs 84% )between the two groups with p= 0.37). The NRM was 12,5 % and it was not statistically different between the four groups(p=0.7) Conclusion Pretransplant obesity was associated with inferior OS after ASCT without impacting treatment related complications.
  • ||||||||||  Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi, Zarzio (filgrastim biosimilar) / Novartis
    [VIRTUAL] EFFECT OF HEMATOPOIETIC STEM CELL TRANSPLANTATION(HSCT)IN SEVERE CONGENITAL NEUTROPENIA () -  May 13, 2021 - Abstract #EHA2021EHA_715;    
    Male to female was 7:4.The median discase course from diagnosis to transplant was 37 (8-165) months.Six patients received umbilical cord blood-HSCT,the conditioning regimen was:Fludarabine(40mg/m2/d×5days)+Ara-c(2g/m2/d×5days)+Bu(0.8mg-1.2mg/KgQ6h×4days)+cyclophosphamide(1.8g/m2/d×2days)+ATG(Thymoglobuline,SANOFI,1.25mg/Kg/d×2days).Two patients underwent matched unrelated donor(MUD)-HSCT,two patients underwent Haplo-HSCT,and another one were sibling donor-HSCT,the conditioning regimen was:Ara-c(3g/m2/d×3days)+Bu(0.8mg-1.2mg/Kg Q6h×4days)+Fludarabine(40mg/m2/d×4days)+ATG(ATG-Fresenius S,4mg/Kg/d×4days or p-ALG 20mg/Kg/d×2days for sibling donor-HSCT).For GVHD prophylaxis,CsA/tacrolimus plus MTX were used...Conclusion Our results have shown that HSCT has higher implantationrate and overall survival rate,and may become a viable therapeutic option. Nevertheless, because of the transplant-related death, a careful selection of HSCT candidates and the time point for HSCT should be undertaken.
  • ||||||||||  Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
    Trial completion date, Trial primary completion date:  Efficacy and Safety Study of ATG for Prophylaxis of aGVHD in Matched Sibling Donor PBSCT (clinicaltrials.gov) -  Sep 23, 2020   
    P4,  N=140, Recruiting, 
    Longer term follow-up is needed to better characterize benign and malignant disease control, graft durability, immune reconstitution, and late toxicities of the platform. Trial completion date: Dec 2018 --> Dec 2025 | Trial primary completion date: Dec 2017 --> Dec 2025
  • ||||||||||  Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi, Lymphoglobuline (equine anti-thymocyte globulin) / Sanofi, NN1213 / Novo Nordisk
    Trial completion date, Trial primary completion date:  The Efficacy of Immunosuppressive Therapy Combined With Cord Blood Transfusion in Treatment of Severe Aplastic Anemia (clinicaltrials.gov) -  Apr 20, 2020   
    P4,  N=120, Recruiting, 
    Conclusion Overall response of 72% with the combination of indigenous equine ATG (thymogam), eltrombopag and cyclosporine in this study in comparison to historical published data with the use of equine ATG and cyclosporine justifies further studies with larger sample size. Trial completion date: Dec 2018 --> Dec 2021 | Trial primary completion date: Dec 2018 --> Dec 2021